Decoy Therapeutics Regains Nasdaq Compliance
Decoy Therapeutics announces that on March 31, the company received notification from the Nasdaq Stock Market that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement and is now in compliance with all other applicable continued listing requirements of The Nasdaq Capital Market. Nasdaq further notified the company that it will be subject to a Mandatory Panel Monitor for a period of one year from March 31. If, within that one-year monitoring period, the Listing Qualifications Staff finds the company out of compliance with the Minimum Bid Price Requirement that was the subject of the exception, the Staff will issue a delisting determination letter and the company will have the opportunity to request a hearing with the Nasdaq Hearings Panel.
